153 related articles for article (PubMed ID: 28575292)
1. Durability of Response After Hepatitis B Surface Antigen Seroclearance During Nucleos(t)ide Analogue Treatment in a Multiethnic Cohort of Chronic Hepatitis B Patients: Results After Treatment Cessation.
Chi H; Wong D; Peng J; Cao J; Van Hees S; Vanwolleghem T; Qi X; Chen L; Feld JJ; de Knegt RJ; Hansen BE; Janssen HLA
Clin Infect Dis; 2017 Aug; 65(4):680-683. PubMed ID: 28575292
[TBL] [Abstract][Full Text] [Related]
2. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B.
Jeng WJ; Chen YC; Chien RN; Sheen IS; Liaw YF
Hepatology; 2018 Aug; 68(2):425-434. PubMed ID: 29108132
[TBL] [Abstract][Full Text] [Related]
3. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
[TBL] [Abstract][Full Text] [Related]
4. Sustained off-treatment viral control is associated with high hepatitis B surface antigen seroclearance rates in Caucasian patients with nucleos(t)ide analogue-induced HBeAg seroconversion.
Van Hees S; Chi H; Hansen B; Bourgeois S; Van Vlierberghe H; Sersté T; Francque S; Wong D; Sprengers D; Moreno C; Nevens F; Janssen HLA; Vanwolleghem T
J Viral Hepat; 2019 Jun; 26(6):766-769. PubMed ID: 30801868
[No Abstract] [Full Text] [Related]
5. Caucasian Ethnicity, but Not Treatment Cessation is Associated with HBsAg Loss Following Nucleos(t)ide Analogue-Induced HBeAg Seroconversion.
Van Hees S; Chi H; Hansen B; Bourgeois S; Van Vlierberghe H; Sersté T; Francque S; Wong D; Sprengers D; Moreno C; Nevens F; Janssen H; Vanwolleghem T
Viruses; 2019 Jul; 11(8):. PubMed ID: 31357522
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability.
Seto WK; Cheung KS; Wong DK; Huang FY; Fung J; Liu KS; Lai CL; Yuen MF
J Gastroenterol; 2016 May; 51(5):487-95. PubMed ID: 26446756
[TBL] [Abstract][Full Text] [Related]
7. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
[TBL] [Abstract][Full Text] [Related]
8. Increased intrahepatic quasispecies heterogeneity correlates with off-treatment sustained response to nucleos(t)ide analogues in e antigen-positive chronic hepatitis B patients.
Chen L; Gan QR; Zhang DQ; Yao LF; Lin RS; Li Q; Lin MH; Yu DM; Zhang XX; Pan C
Clin Microbiol Infect; 2016 Feb; 22(2):201-207. PubMed ID: 26493847
[TBL] [Abstract][Full Text] [Related]
9. Viral determinants predicting hepatitis B surface antigen (HBsAg) seroclearance in HIV-/HBV-coinfected patients.
Strassl R; Reiberger T; Honsig C; Payer BA; Mandorfer M; Grabmeier-Pfistershammer K; Rieger A; Kundi M; Grundtner P; Peck-Radosavljevic M; Popow-Kraupp T
J Viral Hepat; 2014 Jul; 21(7):508-16. PubMed ID: 24112778
[TBL] [Abstract][Full Text] [Related]
10. Predictors of sustained virologic response after discontinuation of nucleos(t)ide analog treatment for chronic hepatitis B.
Peng J; Cao J; Yu T; Cai S; Li Z; Zhang X; Sun J
Saudi J Gastroenterol; 2015; 21(4):245-53. PubMed ID: 26228369
[TBL] [Abstract][Full Text] [Related]
11. Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B.
Papatheodoridi M; Papatheodoridis G
Cells; 2020 Feb; 9(2):. PubMed ID: 32093411
[TBL] [Abstract][Full Text] [Related]
12. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.
Seto WK; Wong DK; Fung J; Huang FY; Lai CL; Yuen MF
Hepatology; 2013 Sep; 58(3):923-31. PubMed ID: 23468172
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients.
He D; Guo S; Zhu P; Tao S; Li M; Huang H; Wang J; Wang Y; Ding M
Clin Microbiol Infect; 2014 Oct; 20(10):O687-93. PubMed ID: 25469947
[TBL] [Abstract][Full Text] [Related]
14. Ten-year follow-up of hepatitis B relapse after cessation of lamivudine or telbivudine treatment in chronic hepatitis B patients.
Pan HY; Pan HY; Chen L; Yang DH; Huang HJ; Tong YX; Chen CR; Yan J
Clin Microbiol Infect; 2015 Dec; 21(12):1123.e1-9. PubMed ID: 26253290
[TBL] [Abstract][Full Text] [Related]
15. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
Buster EH; Schalm SW; Janssen HL
Best Pract Res Clin Gastroenterol; 2008; 22(6):1093-108. PubMed ID: 19187869
[TBL] [Abstract][Full Text] [Related]
16. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
[TBL] [Abstract][Full Text] [Related]
17. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C
Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
[TBL] [Abstract][Full Text] [Related]
18. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
He LT; Ye XG; Zhou XY
World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
[TBL] [Abstract][Full Text] [Related]
19. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
[TBL] [Abstract][Full Text] [Related]
20. Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B.
Höner Zu Siederdissen C; Rinker F; Maasoumy B; Wiegand SB; Filmann N; Falk CS; Deterding K; Port K; Mix C; Manns MP; Herrmann E; Wedemeyer H; Kraft AR; Cornberg M
J Infect Dis; 2016 Nov; 214(10):1492-1497. PubMed ID: 27609808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
